PDL BioPharma (NASDAQ:PDLI) will be releasing its earnings data after the market closes on Wednesday, February 21st. Analysts expect PDL BioPharma to post earnings of $0.11 per share for the quarter.
PDL BioPharma (PDLI) opened at $2.43 on Wednesday. PDL BioPharma has a 12 month low of $1.96 and a 12 month high of $3.55. The company has a quick ratio of 3.10, a current ratio of 3.16 and a debt-to-equity ratio of 0.14. The stock has a market capitalization of $373.50, a P/E ratio of 4.86 and a beta of 0.48.
Several brokerages have issued reports on PDLI. ValuEngine raised PDL BioPharma from a “hold” rating to a “buy” rating in a research note on Saturday, November 25th. Zacks Investment Research lowered PDL BioPharma from a “buy” rating to a “hold” rating in a research note on Monday, January 8th. Cowen reissued a “hold” rating and issued a $3.00 price target on shares of PDL BioPharma in a research note on Friday, October 27th. Finally, BidaskClub lowered PDL BioPharma from a “sell” rating to a “strong sell” rating in a research note on Tuesday. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $3.33.
PDL BioPharma, Inc seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company’s segments include income generating assets and product sales.
Receive News & Ratings for PDL BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDL BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.